| Optoacoustic Detection of Inflammation Using MSOT Device (NCT05333978) | University of Oklahoma | 2022-05-31 |
| Photopheresis in GvHD After Hematopoietic Transplantation: Characteristics of the Procedure and of the Cell Product (NCT05718674) | Fondazione Policlinico Universitario Agostino Gemelli IRCCS | 2022-05-26 |
| MORPHEE : Mechanisms of Cell Death Induced by Extracorporeal Photochemotherapy (NCT05333367) | Centre Hospitalier Universitaire de Besancon | 2022-04-15 |
| Impact of Exercise on the Complications of Corticosteroids in Patients With GVHD: the RESTART Trial (NCT05236062) | Dana-Farber Cancer Institute | 2022-04-14 |
| Extended vs Short-term Abatacept Dosing for Graft Versus Host Disease Prophylaxis (NCT04380740) | Boston Children's Hospital | 2022-03-30 |
| GvHD Prophylaxis in Unrelated Donor HCT: Randomized Trial Comparing PTCY Versus ATG (NCT05153226) | DKMS gemeinnützige GmbH | 2022-03-02 |
| A Randomized Phase II Study to Compare the Potential Long-Lasting Positive Effect of Decidual Stromal Cells to the Best Available Treatment in Graft Versus Host Disease (NCT05132166) | University Health Network, Toronto | 2021-12-22 |
| Evaluation of the Impact of Reduced Immunosuppression (NCT05238155) | Methodist Health System | 2021-10-19 |
| Evaluation of GvHD Damage on Medullary Mesenchymal Stem Cells (NCT05167188) | Azienda Ospedaliera Ospedale Infantile Regina Margherita Sant'Anna | 2021-10-14 |
| IRENE-G Study: Impact of Resistance Exercise and Nutritional Endorsement on GvHD Symptoms (NCT05111834) | University Hospital Heidelberg | 2021-09-15 |
| Evaluation of Dextenza in Patients With Ocular GVHD and Effects on Ocular Surface Disease Outcomes (NCT04728646) | Massachusetts Eye and Ear Infirmary | 2021-09-01 |
| Umbilical Cord Mesenchymal Stem Cells in the Treatment of Moderate/Severe Chronic Graft-versus-host Disease (NCT05152160) | Shenzhen University General Hospital | 2021-08-01 |
| oGVHD After Bone Marrow Transplantation: a Territory-wide Cohort (NCT05170347) | The University of Hong Kong | 2021-04-30 |
| The Influence of Extracorporeal Photopheresis on Skin Sclerosis (NCT04752397) | Charite University, Berlin, Germany | 2021-02-12 |
| Efficacy and Safety of UC-MSCs for the Treatment of Steroid-resistant aGVHD Following Allo-HSCT (NCT04738981) | Peking University People's Hospital | 2021-02-01 |
| IS-free Treg HaploHCT (NCT04678401) | Dana-Farber Cancer Institute | 2021-01-12 |
| GVHD Prophylaxis With Methotrexate in Haploidentical HCT Using Posttransplant Cyclophosphamide (NCT04622956) | University of Sao Paulo General Hospital | 2020-10-07 |
| Sitagliptin for the Treatment of Grade 3-4 and Refractory Acute Graft-versus-host Disease (NCT04448587) | Rabin Medical Center | 2020-10-01 |
| Alterations in Intestinal Microbiota, Metabolites, and Immune Cells in Allo-HSCT (NCT06143501) | The First Affiliated Hospital of Soochow University | 2020-09-01 |
| Haplo Peripheral Blood Sct In GVHD Prevention (NCT04473911) | Zachariah Michael DeFilipp | 2020-08-14 |
| Multidisciplinary Intervention In Chronic GVHD (NCT04479995) | Massachusetts General Hospital | 2020-08-02 |
| Activity, Safety and Pharmacokinetics in Pediatric Subjects With Moderate and Severe Chronic Graft vs. Host Disease After Allogeneic Stem Cell Transplant (NCT03774082) | Novartis Pharmaceuticals | 2020-05-20 |
| ALPN-101 in Steroid-resistant or Steroid-refractory Acute GVHD (NCT04227938) | Alpine Immune Sciences, Inc. | 2020-05-11 |
| Baricitinib for the Prophylaxis of Graft-Versus-Host Disease After Peripheral Blood Hematopoietic Cell Transplantation (NCT04131738) | Washington University School of Medicine | 2020-04-07 |
| Vorinostat for Graft vs Host Disease Prevention in Children, Adolescents and Young Adults Undergoing Allogeneic Blood and Marrow Transplantation (NCT03842696) | University of Michigan Rogel Cancer Center | 2020-02-04 |
| Itacitinib and Tocilizumab for Steroid Refractory Acute Graft Versus Host Disease (NCT04070781) | Columbia University | 2020-01-20 |
| A Feasibility Study Using CLINIMACS® for Alpha/Beta T-Cell Depletion in Stem Cell Transplant (NCT04337515) | Christopher Dvorak | 2019-12-19 |
| Ibrutinib and Rituxan for Chronic GVHD (NCT04235036) | Northside Hospital, Inc. | 2019-12-16 |
| RGI-2001 for the Prevention of Acute Graft-vs-Host Disease in Subjects Following Allogeneic Hematopoietic Stem Cell Transplantation (NCT04014790) | Regimmune Corporation | 2019-11-25 |
| Transfer of Effector Memory T Cells (Tem) Following Allogeneic Stem Cell Transplantation (NCT03836690) | University College, London | 2019-10-21 |
| Pediatric cGVHD Symptom Scale (NCT04044365) | National Cancer Institute (NCI) | 2019-10-02 |
| Study of Brimonidine Tartrate Nanoemulsion Eye Drops in Patients With Ocular Graft-vs-Host Disease (NCT03591874) | Ocugen | 2018-12-23 |
| Feasibility and Efficacy of Modified Donor Lymphocytes Infusion (CD45RA Negative Selected) After Haploidentical Transplantation With Post-transplantation Cyclophosphamide in Patients With Hematological Malignancies (ONC-2016-002). (NCT04687982) | Istituto Clinico Humanitas | 2018-11-13 |
| Cellular Stress Reactions During Graft-versus-host Disease (NCT04558788) | University of Freiburg | 2018-11-01 |
| Peripheral Blood Stem Cell Transplantation From Family Haploidentical Donors in Patients With Myelodysplastic Syndrome and Acute Leukemia Under Primary Prophylaxis With Posaconazole (NCT03434704) | Ciceri Fabio | 2018-06-18 |
| Belimumab for Prevention of Chronic Graft-versus-Host Disease Following Allogeneic Hematopoietic Cell Transplantation (NCT03207958) | Washington University School of Medicine | 2018-05-16 |
| Characteristics and Dynamics of TCR Repertoire in Patients With Hematological Malignancies After Allo-HSCT (NCT03575767) | Affiliated Hospital to Academy of Military Medical Sciences | 2018-05-08 |
| A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD) (NCT03474679) | Janssen Pharmaceutical K.K. | 2018-05-01 |
| The Safety and Tolerability of Pirfenidone for BOS After HCT (NCT03315741) | Stanford University | 2018-03-01 |
| Diadenosine Polyphosphates and Mucin Associated With Ocular Surface Disorders (NCT03731624) | Taipei Tzu Chi Hospital, Buddhist Tzu Chi Medical Foundation | 2018-01-01 |
| Treatment of Oral Mucositis Using Platelet Rich Fibrin TREATMENT OF ORAL MUCOSITIS USING PRF (NCT05018754) | University of Rome Tor Vergata | 2017-07-01 |
| Ruxolitinib In GvHD (NCT02396628) | Prof. Dr. Nikolas von Bubnoff | 2017-06-29 |
| A Phase I/II GVHD Prevention Trial Combining Pacritinib With Sirolimus-Based Immune Suppression (NCT02891603) | H. Lee Moffitt Cancer Center and Research Institute | 2017-06-08 |
| Extended Treatment Protocol for Subjects Continuing to Benefit From Ibrutinib. (NCT03229200) | Pharmacyclics Switzerland GmbH | 2017-05-22 |
| A Study of Acute Graft-Versus-Host Disease (GVHD) in Patients Undergoing Allogeneic Stem-Cell Transplantation (NCT02737306) | CytoDyn, Inc. | 2017-05-14 |
| Precision Diagnostics in Inflammatory Bowel Disease, Cellular Therapy and Transplantation (The PREDICT Trial) (NCT03369353) | Boston Children's Hospital | 2017-05-01 |
| Cyclophosphamide Versus Anti-thymocyte Globulin for GVHD Prophylaxis After RIC Allo-SCT (NCT02876679) | Assistance Publique - Hôpitaux de Paris | 2017-04-06 |
| Topical Vitamin D in Acute Graft Versus Host Disease of the Skin (NCT03093805) | Children's Hospital Medical Center, Cincinnati | 2017-03-15 |
| A Study of CYP-001 for the Treatment of Steroid-Resistant Acute Graft Versus Host Disease (NCT02923375) | Cynata Therapeutics Limited | 2017-03-01 |
| A Phase 2 Study Using Placenta Derived Decidual Stromal Cells for Graft Versus Host Disease (NCT02172924) | Karolinska Institutet | 2017-01-01 |
| 18-FLT PET/MR Imaging to Predict Graft Failure and GVHD in Bone Marrow Transplant Patients (NCT03546556) | UNC Lineberger Comprehensive Cancer Center | 2017-01-01 |
| Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation (NCT02867384) | Dana-Farber Cancer Institute | 2016-11-29 |
| Analysis of Transcriptomic Profile of Graft-versus-host Disease (GHVD) After Allogeneic Grafting of Hematopoietic Stem Cells (NCT03136757) | Centre Hospitalier Universitaire, Amiens | 2016-09-22 |
| A Study to Evaluate the Safety, Tolerability, and Activity of KD025 in Subjects With Chronic Graft Versus Host Disease (NCT02841995) | Kadmon, a Sanofi Company | 2016-09-15 |
| Ruxolitinib for Steroid-refractory GVHD (NCT02997280) | St. Petersburg State Pavlov Medical University | 2016-08-01 |
| Graft-versus-host Disease Associated Myelosuppression (NCT02829216) | Technische Universität Dresden | 2016-04-01 |
| Sitagliptin for Prevention of Acute Graft Versus-Host Disease After Allogeneic Hematopoietic Stem Cell Transplantation (NCT02683525) | Sherif S. Farag | 2016-02-03 |
| Study of BEGEDINA® vs "Conventional Treatment" for Treating Steroid-Resistant Acute GvHD (NCT02411084) | Adienne SA | 2016-02-01 |
| Safety Study of Preimplantation Factor (PIF-1) to Treat Acute Steroid-Resistant Graft-Versus-Host Disease (GVHD) (NCT00517907) | Hadassah Medical Organization | 2016-01-01 |
| The Effect of Folinic Acid Rescue Following MTX GVHD Prophylaxis on Regimen Related Toxicity and Transplantation Outcome (NCT02506231) | Rabin Medical Center | 2015-10-01 |
| Mesenchymal Stem Cells as First Treatment Line for Resistant Acute Graft Versus Host Disease (NCT02770430) | Hospital de Clinicas de Porto Alegre | 2015-09-01 |
| Extended Use of Cannabidiol for the Prevention of Graft-versus-host-disease (NCT02478424) | Rabin Medical Center | 2015-07-01 |
| Comparison of Gut Microbiota, Inflammation and Symptoms Following Allogeneic HSCT (NCT02398708) | University of Florida | 2015-05-01 |
| Cognitive Function and Patient-Reported Quality of Life Outcomes Investigation in Patients Taking Vorinostat (NCT02409134) | Sung Choi, M.D. | 2015-04-01 |
| Safety and Performance Study of the ARGOS-IO System in Patients Undergoing Boston Keratoprosthesis Implantation (NCT02945176) | Implandata Ophthalmic Products GmbH | 2015-03-01 |
| A Phase 1/2 Trial of Donor Regulatory T-cells for Steroid-Refractory Chronic Graft-versus-Host-Disease (NCT02385019) | Instituto de Medicina Molecular João Lobo Antunes | 2015-03-01 |
| Biomarkers in Acute Graft-Versus-Host Disease and Extracorporeal Photopheresis Added to Investigator Chosen Therapies of Steroid Refractory Acute GVHD (NCT02322190) | National Cancer Institute (NCI) | 2014-12-20 |
| Memory T-cell Infusion to Improve Immunity After TCR-alpha/Beta Depleted Hematopoietic Stem Cell Transplantation (NCT02337595) | Federal Research Institute of Pediatric Hematology, Oncology and Immunology | 2014-08-01 |
| Toward Immune Biomarkers for Tolerance and GvHD in Humans (NCT02319226) | Assistance Publique - Hôpitaux de Paris | 2014-05-01 |
| Nonmyeloablative Peripheral Blood Mobilized Hematopoietic Precursor Cell Transplantation for Sickle Cell Disease and Beta-thalassemia in People With Higher Risk of Transplant Failure (NCT02105766) | National Heart, Lung, and Blood Institute (NHLBI) | 2014-04-21 |
| CEC Count Changes to Support GvHD Diagnosis. (NCT02064972) | Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia | 2014-04-01 |
| Safety and Efficacy Study of T-Guard to Treat Steroid-resistant Acute GVHD (NCT02027805) | Xenikos | 2014-03-05 |
| Evaluation of Budesonide and How It Interacts With Antifungal Drugs in People With Gastrointestinal Graft-Versus-Host Disease (NCT01950507) | National Institutes of Health Clinical Center (CC) | 2014-02-20 |
| Treosulfan-TMI Conditioning and Rapamycin GvHD Prophylaxis Before Allo-HSCT (NCT03963024) | IRCCS San Raffaele | 2014-02-12 |
| Atorvastatin as GVHD Prophylaxis for Allogeneic Hematopoietic Cell Transplantation (NCT01665677) | Mehdi Hamadani | 2014-01-20 |
| Preemptive Therapy of GVHD (NCT01994824) | University of Calgary | 2014-01-01 |
| A Randomized, Controlled, Double-Masked, Clinical Trial of Autologous Serum Eye Drops for Severe Ocular Chronic Graft-versus-Host Disease (GVHD) in Hematopoietic Stem Cell Transplant (HSCT) Patients (NCT01972438) | National Eye Institute (NEI) | 2013-11-01 |
| A Pilot Study of Alpha-1-Antitrypsin (AAT) in Steroid Refractory Acute Graft vs Host Disease (NCT01700036) | University of Michigan Rogel Cancer Center | 2013-07-01 |
| Chronic GVHD Response Measures Validation (NCT01902576) | Fred Hutchinson Cancer Center | 2013-06-01 |
| Collection of Saliva and/ or Peripheral Blood From Healthy Volunteers for Research (NCT01851382) | National Cancer Institute (NCI) | 2013-05-15 |
| Tacrolimus, Sirolimus and Ustekinumab vs. Tacrolimus and Sirolimus for the Prevention of Acute Graft-Versus-Host Disease (NCT01713400) | H. Lee Moffitt Cancer Center and Research Institute | 2013-02-25 |
| Abatacept as GVHD Prophylaxis Phase 2 (NCT01743131) | Boston Children's Hospital | 2013-02-01 |
| Vulvovaginal Graft Versus Host Disease (VV-GVHD) in Women Who Underwent Transplantation Before and After Menarche (NCT01512498) | Hadassah Medical Organization | 2012-12-01 |
| Pomalidomide for Chronic Graft-versus-Host Disease (NCT01688466) | National Cancer Institute (NCI) | 2012-08-30 |
| Brentuximab Vedotin for Steroid Refractory GvHD (NCT01596218) | Massachusetts General Hospital | 2012-07-01 |
| Tacrolimus/Methotrexate Versus Cyclosporine/Methotrexate for Prophylaxis of Graft Versus Host Disease (NCT01788501) | Seoul National University Hospital | 2011-11-01 |
| Efficacy Study of Azithromycin-based Therapy for Bronchiolitis Obliterans (NCT01327625) | Asan Medical Center | 2011-03-01 |
| Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (NCT01206309) | Fred Hutchinson Cancer Center | 2011-03-01 |
| Cyclosporine Inhalation Solution (CIS) in Lung Transplant and Hematopoietic Stem Cell Transplant Recipients for the Treatment of Bronchiolitis Obliterans Syndrome (NCT01287078) | National Heart, Lung, and Blood Institute (NHLBI) | 2011-01-29 |
| Decidual Stromal Cells as Treatment for Acute Graft Versus Host Disease, a Phase 1-2 Study (NCT02172937) | Karolinska Institutet | 2011-01-01 |
| Safety Study of Homeo-GH (Bone Marrow Derived Clonal Mesenchymal Stem Cell) to Treat Acute/Chronic Graft Versus Host Disease (GVHD) (NCT01318330) | HomeoTherapy Co., Ltd | 2010-11-01 |
| Impact of Adnexal Involvement of the Severity and Prognosis of Chronic Graft-versus-Host Disease (NCT01221766) | Dana-Farber Cancer Institute | 2010-09-01 |
| Atorvastatin for the Prophylaxis of Acute GVHD in Patients Undergoing Matched Sibling Allogeneic Transplantation (NCT01175148) | West Virginia University | 2010-07-01 |
| Cord Blood Serum in the Treatment of Ocular Surface Diseases (NCT01234623) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2010-02-01 |
| Evaluation of Antifungal Prophylaxis on Graft-versus-host Disease (GVHD) Patients (NCT01282879) | Samsung Medical Center | 2009-12-01 |
| Combination of Alemtuzumab and Rituximab at Low-doses in Refractory Chronic Graft-Versus-Host Disease (NCT01042509) | Hospital Universitario Dr. Jose E. Gonzalez | 2009-10-01 |
| Mesenchymal Stromal Cells (MSCs) for the Treatment of Graft Versus Host Disease (GVHD) (NCT01764100) | Ettore Biagi, MD | 2009-09-01 |
| CC-4047 (Pomalidomide) for Graft vs. Host Disease (NCT00770757) | Washington University School of Medicine | 2009-02-01 |
| Vorinostat to Prevent Graft Versus Host Disease Following Reduced Intensity, Related Donor Stem Cell Transplant (NCT00810602) | Pavan Reddy, MD | 2009-01-01 |
| A Pilot Study of Imatinib Mesylate in Steroid Refractory Chronic Graft Versus Host Disease (NCT00760981) | David Miklos | 2008-09-01 |